JUPITER, Fla., Jan. 11, 2021 /PRNewswire/ — Jupiter Orphan Therapeutics, Inc. (“JOT”) a biotechnology company pioneering a novel and disease modifying product named JOTROL™, today announced that the first patient has been dosed in a Phase I dose escalation study of JOTROL™.
To read the full article, click here.